Neuros Therapeutics raises $25M Series B for AI-guided adaptive DBS in South Korea and Japan
Summary
Seoul-based Neuros Therapeutics secured ₩33B ($25M) Series B led by Korea Investment Partners, with IMM Investment and Sumitomo Pharma Ventures Japan, to advance their AI-guided adaptive DBS system for Parkinson's disease into pivotal trials in South Korea and Japan simultaneously. KFDA breakthrough device designation received; PMDA consultation underway.
Why it matters
Simultaneous Korean and Japanese pivotal trial strategy is ambitious but strategically sound — both markets have large aging populations, high Parkinson's prevalence, and established DBS reimbursement. Sumitomo Pharma Ventures joining the round creates a potential Japanese distribution partner for Neuros Therapeutics' future commercial launch.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial